Karyopharm Therapeutics
KPTI
#9196
Rank
โ‚น15.23 B
Marketcap
โ‚น672.21
Share price
-0.85%
Change (1 day)
77.26%
Change (1 year)

Revenue for Karyopharm Therapeutics (KPTI)

Revenue in 2026 (TTM): โ‚น13.50 Billion

According to Karyopharm Therapeutics 's latest financial reports the company's current revenue (TTM ) is โ‚น14.44 Billion. In 2025 the company made a revenue of โ‚น13.11 Billion an increase over the revenue in the year 2024 that were of โ‚น12.45 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Karyopharm Therapeutics from 2013 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚น13.50 B2.97%
2025 โ‚น13.11 B5.24%
2024 โ‚น12.45 B2.49%
2023 โ‚น12.15 B-6.47%
2022 โ‚น12.99 B-16.77%
2021 โ‚น15.61 B97.57%
2020 โ‚น7.90 B171.07%
2019 โ‚น2.91 B37.48%
2018 โ‚น2.12 B1969.83%
2017 โ‚น0.10 B879.27%
2016 โ‚น10.46 M-37.01%
2015 โ‚น16.61 M14.97%
2014 โ‚น14.45 M-39.56%
2013 โ‚น23.9 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Abbott Laboratories
ABT
โ‚น4.315 T 29,766.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
โ‚น6.288 T 43,420.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น4.635 T 31,982.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Exelixis
EXEL
โ‚น227.14 B 1,471.94%๐Ÿ‡บ๐Ÿ‡ธ USA